Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Open, Noninterventional, Multicentre Trial of Rituximab in Combination With Chemotherapy (CVP, CHOP or FCM) Chemotherapy in Patients With Follicular Lymphoma

The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.

Inclusion Criteria:

• New diagnosed Stage III/IV NHLs
• Grades 1, 2 follicular lymphoma need to be treated
• mCD20 positive
• Have an expected survival of 3 months or more
• ECOG 0-2 grade
• Normal renal function
• ALT less than double normal level

Exclusion Criteria:

• Presence of CNS lymphoma
• Severe infectious disease or organic disease
• Having another malignant tumor
• Pregnant or breast-feeding female
• Organic heart disease, heart failure, II or higher grade AV bundle block.
• Subject is allergic to Rituximab
• Known HIV infection or chronic HBV infection